-- RBT-101, Radiant's lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model -- Poster ...
By Daniella Parra Radiant Biotherapeutics presented data from their advancing a breakthrough antibody approach, the Multabody ...
Radiant Biotherapeutics to present new data from lead oncology programme at SITC 2025 annual meeting
Radiant Biotherapeutics to present new data from lead oncology programme at SITC 2025 annual meeting: Toronto Thursday, November 6, 2025, 18:00 Hrs [IST] Radiant Biotherapeutics, ...
8d
Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting
Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody™, for a broad range of therapeutic areas, including cancer and infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback